ReviewBioengineering (Basel, Switzerland)2023
Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics.
Review in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 120 citations in OpenAlex.
- Employing Streptomyces enissocaesilis as a sustainable cell factory for green synthesis of gold nanoparticles with multi-target anticancer activity against MCF-7 breast cancer cells.Microbial cell factories · 2026Article
- Fabrication of methotrexate conjugated multi-walled carbon nanotubes for the evaluation of cytotoxic potential at biochemical and molecular level modulatingRSC advances · 2026Article
- Biochemical and Biotechnological Approaches to Disease Diagnosis and Therapeutics: A Comprehensive Review.Cureus · 2026Review
- <p>Regulatory networks of HIFs in tumor‑infiltrating immune cells: From molecular mechanisms to therapeutic implications (Review)</p>.International journal of oncology · 2026Review
- Bioactive glass nanoparticles induce pronounced cytotoxicity in human hepatocellular carcinoma Hep-G2 cells through ROS-mediated genomic instability and mitochondrial apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Anticancer Potential of Cannabidiol in Renal Cell Carcinoma: Serum Modulation and Preliminary Mechanistic Insights.Journal of clinical medicine · 2026Article
- Antiviral Properties of Green-Synthesized Silver and Zinc Oxide Nanoparticles Against Coronaviruses: A Review.International journal of microbiology · 2026Review
- Pathophysiological and Etiological Corroborations for the Mechanistic Design of Intranasal Therapies in Glioblastoma Multiforme.Current pharmaceutical design · 2026Review
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and Artificial Intelligence- Based Screening and Treatment.Current treatment options in oncology · 2025Review
- Targeted delivery of doxorubicin to B-cell lymphoma using monoclonal antibody-functionalized Chaetoceros biosilica.Scientific reports · 2025Article
- The Toxicological Profile of Active Pharmaceutical Ingredients-Containing Nanoparticles: Classification, Mechanistic Pathways, and Health Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics.Journal of nanobiotechnology · 2025Review
- Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations.Discover oncology · 2025Review
- A comprehensive review on the latest advances of dimeric anticancer prodrugs.Future medicinal chemistry · 2025Review
- Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems.Pharmaceutics · 2025Review
- A quality-by-design approach to develop abemaciclib solid lipid nanoparticles for targeting breast cancer cell lines.Therapeutic delivery · 2025Article
- Review
- DSPE-mPEG2000-Modified Podophyllotoxin Long-Circulating Liposomes for Targeted Delivery: Their Preparation, Characterization, and Evaluation.Current drug delivery · 2025Article
- Recent Update on Nanoparticles Based Approaches for Management of Cancer: Wave from Traditional to Advanced Technology.Current cancer drug targets · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Nano-oncology is a branch of biomedical research and engineering that focuses on using nanotechnology in cancer diagnosis and treatment. Nanomaterials are extensively employed in the field of oncology because of their minute size and ultra-specificity. A wide range of nanocarriers, such as dendrimers, micelles, PEGylated liposomes, and polymeric nanoparticles are used to facilitate the efficient transport of anti-cancer drugs at the target tumor site. Real-time labeling and monitoring of cancer cells using quantum dots is essential for determining the level of therapy needed for treatment. The drug is targeted to the tumor site either by passive or active means. Passive targeting makes use of the tumor microenvironment and enhanced permeability and retention effect, while active targeting involves the use of ligand-coated nanoparticles. Nanotechnology is being used to diagnose the early stage of cancer by detecting cancer-specific biomarkers using tumor imaging. The implication of nanotechnology in cancer therapy employs photoinduced nanosensitizers, reverse multidrug resistance, and enabling efficient delivery of CRISPR/Cas9 and RNA molecules for therapeutic applications. However, despite recent advancements in nano-oncology, there is a need to delve deeper into the domain of designing and applying nanoparticles for improved cancer diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.